Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

Multiple Sclerosis

Volumn 16, Issue 11, 2010, Pages 1360-1366

  Comi, G ^a   Abramsky, O ^b   Arbizu, T ^c   Boyko, A ^d   Gold, R ^e   Havrdova E ^f   Komoly, S ^g   Selmaj, K ^h   Sharrack, B ⁱ   Filippi, M ^j  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^e ST JOSEF HOSPITAL   (Germany)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY OF PÉCS   (Hungary)

^h MEDICAL UNIVERSITY OF LODZ   (Poland)

ⁱ UNIVERSITY OF SHEFFIELD   (United Kingdom)

^j Institute of Experimental Neurology   (Italy)

more..

Author keywords

Gadolinium enhanced T1 lesions; immunomodulator; MRI; multiple sclerosis; relapsing remitting

Indexed keywords

GADOLINIUM; LAQUINIMOD; LIVER ENZYME; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLEEDING; BRAIN DAMAGE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; GRAND MAL EPILEPSY; HEPATOMEGALY; HUMAN; HYPOPHYSIS TUMOR; LEIOMYOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE CRAMP; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; RETINA DEGENERATION; SIDE EFFECT; TREATMENT DURATION;

ADMINISTRATION, ORAL; BRAIN; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUINOLONES;

EID: 78449302875     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510378127     Document Type: Article

References (11)

1. Compston ACC, Lassmann H., McDonald I., et al. McAlpine's Multiple Sclerosis, 4 th edn. Philadephia, PA: Churchill Livingstone Elsevier, 2004.
2. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 ; 45: 1268-1276.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 ; 39: 285-294.
4. The PRISMS (Prevention of relapses and disability by interferon β-1a subcutaneously in multiple sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998 ; 352: 1498-1504.
5. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995 ; 45: 1277-1285.
6. Polman CH, O'Connor PW, Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
7. Millefioini E., Gasperini C., Pozzilli C., et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997 ; 244: 153-159.
8. Polman C., Barkhoff F., Sandberg-Wolheim M., et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005 ; 64: 987-991.
9. Comi G., Pulizzi A., Rovaris M., et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet 2008 ; 371: 2085-2092.
10. Rovaris M., Capra R., Martinelli V., et al. Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. J Neurol Sci 1999 ; 171: 130-134.
11. Rovaris M., Bastianello S., Capra R., Comi G., Yousry TA and Filippi M. Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. Magn Reson Imaging 1999 ; 17: 985-988.